HIV Persistence

TUESDAY DECEMBER 12, 2017

	Power Point presentations available only with authors' agreement of publication
2.00 3.30	NIH MARTIN DELANEY COLLABORATORIES SATELLITE SYMPOSIUM Research Highlights from Martin Delaney Collaboratory Leaders Keith Jerome, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

	CARE – Collaboratory of AIDS Researchers for Eradication David Margolis, University of North Carolina, Chapel Hill, US I4C – Combined Immunologic Approaches to Cure HIV-1 Dan Barouch, Beth Israel Deaconess Medical Center, Boston, US DARE – Delaney AIDS Research Enterprise to Cure HIV Steven Deeks, University of California, San Francisco, US

4.00 5.30	Chairs: Lillian Kuo, National Institute of Allergy and Infectious Diseases, Bethesda, US David McDonald, National Institute of Allergy and Infectious Diseases, Bethesda, US

	BELIEVE – Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication Douglas Nixon, George Washington University, Washington DC, US DefeatHIV – Delaney Cell and Genome Engineering Initiative Keith Jerome, Fred Hutchinson Cancer Research Center, Seattle, US BEAT-HIV – Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy Luis Montaner, The Wistar Institute, Philadelphia, US

6.00	WELCOME Alain Lafeuillade, General Hospital, Toulon, FR

6.05	OPENING LECTURE Introduction: Karl Salzwedel, National Institute of Allergy and Infectious Diseases, Bethesda, US

	Sustained ART-Free HIV Remission: Obstacles and Opportunities Anthony S. Fauci, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, US Long-term Virological Suppression Mediated by AAV-delivered Antibodies Ronald C. Desrosiers, University of Miami Miller School of Medicine, Miami, US

6.00	WELCOME DINNER

WEDNESDAY DECEMBER 13, 2017

	Power Point presentations available only with authors' agreement of publication
8.00 10.00	SESSION 1: BASIC SCIENCE OF HIV LATENCY I Chairs: Vicente Planelles, University of Utah School of Medicine, Salt Lake City, US Carine Van Lint, University of Brussels, Gosselies, BE

	 OP 1.0: Understanding persistence of the latent reservoir Author: Robert Siliciano Johns Hopkins University School of Medicine, Howard Hughes Medical Institute, Baltimore, MD, US  OP 1.1: HIV-1 proviruses which are integrated into cancer-related genes are inducible Authors: A. Varabyou1, C. Talbot Jr.2, H. Zhang3, S. Beg2,4, R. Pollack2, H. Hao2, J. Margolick3, R. F. Siliciano2,4, M. Pertea2, Y.-C. Ho5 1 Johns Hopkins Whiting School of Engineering, Baltimore, MD, US 2 Johns Hopkins School of Medicine, Baltmore, MD, University of North Carolina, Chapel Hill, US 3 Johns Hopkins School of Public Health, Baltimore, MD, US 4 Howard Hughes Medical Institute, Baltimore, MD, US 5 Yale University School of Medicine, New Haven, CT, US  OP 1.2: The Contribution Of Memory CD4+ T Cell Subset Phenotype TO Latency Reversal Efficiency Authors: D. A. Kulpa1, A. Talla2, S. Ribeiro2, R. Barnard3, D. Hazuda3, N. Chomont4, R. Pierre Sékaly2. 1 Emory University, Atlanta, US 2 Case Western Reserve University, Cleveland, US 3 Merck & Co. Inc., Kenilworth, US 4 Case Western Reserve, Cleveland, US  OP 1.3: Identification of a Promising New Class of Latency Reversing Agents Authors: A. Gramatica, W. Greene, R. Schwarzer, M. Montano, T. Packard, E. Herzig Gladstone Institute of Virology and Immunology, San Francisco, US  OP 1.4: High-throughput single-cell transcriptome analysis of immune cells from HIV-1 infected individuals before and after therapy Authors: T. Bradley 1 , C. Hart 1, B. Hora 1, J. Pollara 1, E. P. Browne 2, M. Anthony Moody1, Guido Ferrari1, David Margolis2, and Barton F. Haynes1 1 Human Vaccine Institute, Duke Human Vaccine Institute, Durham, US 2 University of North Caroline HIV Cure Center, UNC Chapel Hill, Chapel Hill, US  OP 1.5: CD32 does not mark the HIV-1/SIV latent reservoir Authors: C. E. Osuna1, R. Apps2, S.-Y. Lim1, J. L. Kublin1, R. Thomas3, E. Chen1, G. Yoon1, S. Han Huang2, D. Chan2, R. Truong2, Y. Ren 2, N. D. Bachtel2, M. E. Ackerman4, J. Ananworanich3, D. H. Barouch1,5, N. L. Michael3, R. Brad Jones2, D. F. Nixon2, J. B. Whitney1,5, the BELIEVE Collaboratory 1 Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, US 2 Department of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington DC, US 3 United States Military HIV Research Program, Bethesda, MD, US 4 Thayer School of Engineering, Dartmouth College, Hanover, DE 5 Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, US  OP 1.6: Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-infected Cells Authors: M.Golumbeanu1,2, S. Rato3, S. Cristinelli3, M. Munoz3, M. Cavassini4, N. Beerenwinkel1,2, A. Ciuffi3 1 Department of Biosystems Science and Engineering, ETH Zürich, Basel, CH 2 SIB Swiss Institute of Bioinformatics, Basel, CH

10.30 12.30	SESSION 2: BASIC SCIENCE OF HIV LATENCY II Chairs: Brian A. Johns, Glaxo SmithKline’s director of HIV medicinal chemistry, Raleigh-Durham, US Guenter Kraus, Director of Janssen, BE

	 OP 2.0: Characterizing HIV Expression of Proviruses during ART in Tissues and Blood Author: M. Kearney HIV Dynamics and Replication Program, CCR, National Cancer Institute, Frederick, MD, US  OP 2.1: The HIV-1 antisense transcript AST recruits the Polycomb Repressor Complex 2 to the HIV-1 5’LTR and acts as a viral latency factor Authors: F. Romerio 1, J.C. Zapata 1, R. Barclay 2, M.D. Iglesias-Ussel 1 F. Kashanchi 2 1 Institute of Human Virology, Baltimore, MD, US 2 George Mason University, Manassas, VA, US  OP 2.2: Majority of the Latent Reservoir Resides in CD32a Negative CD4+ T Cells Authors: L. N. Bertagnolli, J. A. White, S. A. Beg, F. R. Simonetti, J. Lai, C. Tomescu, A. J. Murray, Annukka A. R. Antar, Hao Zhang, J. B. Margolick, L. J. Montaner, R. F. Siliciano, G. M. Laird, J. D. Siliciano 1 Johns Hopkins University School of Medicine, Baltimore, US  OP 2.3: Brain Macrophages in SIV-infected ART-Suppressed Macaques Represent a Functional Latent Reservoir Authors: J. Clements1, C. Abreu1, F. Mac Gabhann 2, J. Mankowski1, L. Gama1 1 Johns Hopkins School of Medicine, Baltimore, US 2 Johns Hopkins University, Baltimore, US  OP 2.4: CD4+ T Cells Expressing CD32 From HIV-1+ Patients Are Not Enriched for Proviral DNA Authors: A. M. Spivak, R. A. Nell, M. L. Coletti, L. J. Montaner, V. Planelles University of Utah, Salt Lake City, US  OP 2.5: The impact of ART duration on the infection of T cells within anatomic sites Authors: E. Lee1,2, S. von Stockenstrom3, V. Morcilla1, W. Shao4, W. Hartogensis5, P. Bacchetti6, J. Milush5, R. Hoh5, M. Somsouk5, P. W. Hunt5, R. Fromentin7, N. Chomont7, S. G. Deeks5, Fr. M. Hecht5, S. Palmer1,2, 1 The Westmead Institute for Medical Research, NSW, AU 2 University of Sydney, NSW, AU 3 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Karolinska University Hospital, Stockholm, SE 4 Advanced Biomedical Computing Center, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, US 5 Department of Medicine, University of California San Francisco, San Francisco, California, US 6 Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, US 7 Centre de recherche du CHUM and Department of microbiology, infectiology and immunology, Université de Montréal, Montreal, CA  OP 2.6: CD32+ CD4+ T Cells Are HIV Transcriptionally Active Rather than a Resting Reservoir Authors: M. Abdel-Mohsen1, C. Tomescu1, S. Vadrevu1, A. Spivak2, L. Kuri-Cervantes3, G. Wu4, K. Cox4, S. Vemula4, M. Fair1, K. Lynn1,3, M. J. Buzon5, J. Martinez-Picado6, M. Betts3, V. Planelles2, K. Mounzer7, B. Howell4, D. Hazuda4, P. Tebas3, L. J. Montaner1 1 The Wistar Institute, PA, US 2 University of Utah School of Medicine, UT, US 3 University of Pennsylvania, PA, US 4 Merck & Co, Inc, NJ, US 5 Vall d´Hebron Research Institute, ES 6 IrsiCaixa, UVic-UCC & ICREA, Barcelona, ES 7 Jonathan Lax Center, Philadelphia FIGHT, PA, US

2.00 4.00	SESSION 3: IN VITRO AND ANIMAL MODEL STUDIES OF HIV PERSISTENCE Chairs: Victor Garcia Martinez, University of North Carolina, Chapel Hill, US Jeff D. Lifson, Frederick National Laboratory, Frederick, US

	 OP 3.0: Testing cure approaches in NHPs: the Emory experience Author: G. Silvestri Emory University and Yerkes National Primate Research Center Atlanta, US  OP 3.1: Visualization and quantification of HIV dissemination and reservoirs using in vivo imaging Authors: W-B. Young 1, X. Qu 2, G. Wu2 1 Temple University, Philadelphia, US, 2 University of Pittsburgh, Pittsburgh, US  OP 3.2: Enhancing Infection-Resistant Cells for HIV Cure in the Nonhuman Primate Model Authors: C. W. Peterson1, 2, A. Zhen3, C. Deleage4, J. D. Estes4, S. Kitchen3, and H.-P. Kiem1,2 1 Fred Hutchinson Cancer Research Center, Seattle, WA, US 2 University of Washington, Seattle, WA, US 3 UCLA, Los Angeles, CA, US 4 AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, US  OP 3.3: Modeling the graft-versus-viral-reservoir effect in a nonhuman primate model of HIV persistence Authors: C. W. Peterson1, 2, L. Colonna3, J. B. Schell3, J. M. Carlson3, S. S. Reddy1, W. Obenza1, H.-P. Kiem1,3, and L. Kean2,3 1 Fred Hutchinson Cancer Research Center, Seattle, WA, US 2 University of Washington, Seattle, WA, US 3 Seattle Children’s Research Institute, Seattle, WA, US  OP 3.4: Patient-Derived HIV Reservoirs can be Stably Engrafted into NSG Mice and Reactivated by Latency-Reversing Agents in vivo Authors: A. Ward1, E. Charleus1, S. Karandish1, E. Benko2, C. Kovacs2, D. Chan1, A. Ramezani1, R. Brad Jones1 1 Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University, Washington DC, US 2 Maple Leaf Medical Clinic, Toronto, ON, CA  OP 3.5: SIV Persists in Lymphoid Tissues Despite Alemtuzumab-Induced CD4+ T Cell Depletion Authors: A. A. Okoye1,2, S. R. Lewin6,7, C. H. Xu1,2, M. Vaidya1,2, D. M. Duell1,2, W. B. Brantley1,2, M. A. Marenco1,2, Y. Fukazawa1,2, H. M. Park1,2, T. A. Rasmussen3, J. D. Lifson4, M. K. Axthelm1,2, S. G. Deeks5, L. J. Picker1,2 1 Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, US 2 Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, US 3 Department of Infectious Diseases, Aarhus University Hospital, Aarhus, DK 4 AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, MD, US 5 School of Medicine, University of San Francisco, San Francisco, CA, US 6 The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Victoria, AU 7 Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Victoria, AU  OP 3.6: Differential viral rebound between lymph node and colon after treatment interruption in SHIV-infected rhesus macaques Authors: D. C. Hsu1,2,3, D. Silsorn1, Authors: D. C. Hsu1,2,3, D. Silsorn1, D. Inthawong1, Y. Kuncharin1, J. Sopanaporn1, S. Tayamun1, R. Im-Erbsin1, C. Ege1, M. Wegner1, P. Sunyakumthorn1, R. J. O’Connell1,2, N. L. Michael2, S. Vasan1,2,3 1 Armed Forces Research Institute of Medical Sciences, Bangkok, TH 2 US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, US 3 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, US

THURSDAY DECEMBER 14, 2017

Power Point presentations available only with authors' agreement of publication

8.00

10.00

SESSION 4: VIROLOGY OF HIV PERSISTENCE

Chairs: Douglas Richman, University of California, San Diego, US
John Mellors, University of Pittsburgh, Pittsburgh, US

 OP 4.0: Title to be confirmed

Author: D. Hazuda Merck & Co, Inc, NJ, US

 OP 4.1: HIV-1 mediated insertional activation of STAT5B and BACH2 promotes the formation of a viral reservoir in T regulatory cells

Authors: D. Cesana1, F. Santoni de Sio1, L. Rudilosso1, P. Gallina1, A. Calabria1, E. Bruzzesi2, L. Passerini1, S. Nozza2, E. Vicenzi3, G. Poli3, S. Gregori1, G. Tambussi2, E. Montini1

1 San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute, IT

2 Department of Infectious Diseases, San Raffaele Scientific Institute, IT

3 Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, IT

 OP 4.2: Productive HIV-1 infection upregulates CD32 in vitro and in vivo

Authors: C. Serra-Peinado1, J. Grau-Expósito1, M. Genescà1, L. Luque-Ballesteros1, A. Astorga1, C. Gálvez2, J. Castellví3, R. Willekens1, I. Ocaña1, J.Burgos1, J. Navarro1, A. Curra1, E. Ribera1, L. Montaner4, V. Falcó1, J. Martinez-Picado2,5, M. J. Buzon1

1 Infectious Disease Department, Hospital Universitari Vall d’Hebrón, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, ES

2 Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, ES

3 Department of Pathology, Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, ES

4 HIV-1 Immunopathogenesis Laboratory, Wistar Institute, Philadelphia, Pennsylvania, US

5 AIDS Research Institute IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, ES

 OP 4.3: No evidence for ongoing HIV replication in lymph nodes during suppressive ART

Authors: W. R. McManus1, M. J. Bale1, J. Spindler1, A. Wiegand1, A. Musick1, X. Wu2, D. Wells2, S. H. Hughes1, B. F. Keele2, R. Hoh3, J. Mulish3, J. M. Coffin4, J. W. Mellors5, S. G. Deeks3, M. F. Kearney1

1 HIV Dynamics and Replication Program, CCR, National Cancer Institute, Frederick, MD, US

2 Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, US

3 Department of Medicine, University of California, San Francisco, San Francisco, CA, US

4 Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, US

5 Department of Medicine, University of Pittsburgh, Pittsburgh, PA, US

 OOP 4.4: Tissue macrophages are a major viral reservoir in male urethra of HIV-1-infected individuals under suppressive anti-retroviral therapy

Authors: M. Bomsel1, Y. Ganor1, A. Sennepin1, C.A. Dutertre1, S. Cristofari2, F. Real1, C. Capron3, E. A. Eugenin4, M. Revol2, A. Hosmalin1

1 Institut Cochin, Paris, FR

2 Saint-Louis Hospital, Paris, FR

3 Ambroise Paré Hospital, Boulogne, FR

4 Ambroise Paré Hospital, Boulogne, FR

 OP 4.5: In vivo massive expansion of a T-cell clone carrying a defective HIV genome: implication for the measurement of the HIV reservoir

Authors: R. Fromentin1, M. Massanella1, C. Vandergeeten3, K. Barton4,5, B. Hiener4,5, W.W. Chiu6,7, D. Looney6,7, M. Ramgopal8, D.D. Richman6,7, L. Trautmann9,10, S. Palmer4,5, N. Chomont1,2

1 CRCHUM, Montreal, CA

2 Université de Montréal, Department of Microbiology, Infectiology and Immunology, Montreal, CA

3 VGTI-FL, Port St Lucie, US

4 The Westmead Institute of Medical Research, Sydney, AU

5 The University of Sydney, Sydney, AU

6 VA San Diego Healthcare System, San Diego, US

7 University of California San Diego, San Diego, US

8 Midway Immunology & Research Center, Fort Pierce, US

9 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, US

10 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, US

 OP 4.6: Gut and blood differ in mechanisms governing HIV transcription/latency

Authors: S. Telwatte1,2, S. Lee2, M. Somsouk2, H. Hatano2, C. Baker2, P. Kim1, T.-H. Chen2, J. Milush2, P. Hunt2, S. Deeks2, J. K. Wong1,2, S. A. Yukl31,2

1 Department of Medicine, San Francisco VA Health Care System, San Francisco, CA, US

2 Department of Medicine, University of California, San Francisco, San Francisco, CA, US

10.30

12.30

SESSION 5: IMMUNOLOGY OF HIV PERSISTENCE

Chairs: Nicolas Chomont, Université de Montreal, Montreal, CA
Richard Koup, Bethesda, Maryland, US

 OP 5.0: The Role of B Cell Follicles in HIV Replication and Persistence

Author : E. Connick
Division of Infectious Diseases, University of Arizona, AZ, US

 OP 5.1: Platelets from HIV-infected cART-treated patients carry infectious viruses and predict poor immunological recovery

Authors: M. Bomsel1, F. Real1, C. Capron2, E. Cramer2, E. Rouveix2

1 Institut Cochin, Paris, FR

2 Ambroise Paré Hospital, Boulogne, FR

 OP 5.2: Follicular Regulatory T cell dynamics in peripheral blood and lymphoid tissue during very early treatment initiation in HIV-1 clade C infection

Authors: F. Laher1, Z.M. Ndhlovu1,3, O. Baiyegunhi1, F. Ogunshola1, V. Ramsuran2, K. Pretorius1, N. Mewalal1, T. Nkosi1, N. Ismail1, B. D. Walker1,3,4, T. Ndung’u1,3,5,6

1 HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, ZA

2 KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, ZA

3 Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, US

4 Howard Hughes Medical Institute, Chevy Chase, Maryland, US

5 Africa Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, ZA

6 Max Planck Institute for Infection Biology, Charitestraße 1, Berlin, DE

 OP 5.3: Single cell analysis of HIV latency reveals diverse proviral and host cell behavior

Authors: E. P Browne1, T. Bradley2, G. Ferrari2, B. F Haynes2 and D. M Margolis1

1 UNC HIV Cure Center and Department of Medicine, University of North Carolina, Chapel Hill, US

2 Duke University, Human Vaccine Institute, Duke University School of Medicine, Durham, NC, US

 OP 5.4: BCL-2 Inhibitor Sensitizes the Latent HIV Reservoir to Elimination by CTLs

Authors: S-H. Huang1, Y. Ren1, A. Macedo1, S. Patel2, D. Chan1, E. Horch1, R. Truong1, C. Bollard2, A. Bosque1, R.B. Jones1

1 Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, Washington, D.C., US

2 Center for Cancer and Immunology Research, Children’s National Health System, Washington D.C., US

 OP 5.5: Defining the nature of protective CD8+ T-cell response in lymph nodes of HIV elite controllers

Authors: M. Betts1, S. Nguyen1, C. Deleage2, S. Deeks3, M. Buggert4, A. Sada-Japp1, A. Naji1, G. Reyes-Teran5, P. Del Rio Estrada5, J. Estes6

1 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadephia, US

2 National Institutes of Health, Frederick, US

3 University of California San Francisco, San Francisco, US

4 University of Pennsylvania, Philadelpia, US

5 CIENI-INER, Mexico City, MX

6 NIH/NCI, Rockville, Maryland, US

 OP 5.6: Susceptibility to Neutralization by bnAbs Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs

Authors: Y. Ren1, M. Korom1, R. Truong1, S.-H. Huang1, D. Chan1, C. Kovacs2, E. Benko2, R. Lynch1, R.B. Jones1

1 Dept. of Microbiology Immunology and Tropical Medicine, The George Washington University, Washington DC, US

2 Maple Leaf Medical Clinic, Toronto, CA

2.00

4.00

SESSION 6: HUMAN STUDIES

Chairs: Sharon Lewin, Doherty Institute University of Melbourne, Melbourne, AU
Jean-Pierre Routy, McGill University, Montreal, CA

 OP 6.0: Current efforts in latency reversal and clearance

Author : D. Margolis
University of North Carolina HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, US

 OP 6.1: HIV-seroreversion dynamics after allogeneic stem cell transplantation

Authors: M. Salgado1, V. González2, B. Rivaya2, Cr. Gálvez1, M. Kwon3, J. Badiola4, A. Bandera5, B. Jensen6, L. Vandekerckhove7, K. Raj8, M. Nijhuis9, Manuel Jurado4, J. Schulze zur Wiesch10, A. Saez-Cirión11, J. Luis Diez-Martin3, A. Wensing9, J. Martinez-Picado1, for the IciStem Consortium

1 AIDS Research Institute, IrsiCaixa, Badalona, ES

2 Microbiology Service, University Hospital “Germans Trias i Pujol”, Department of Genetics and Microbiology, Autonomous University of Barcelona, Badalona, ES

3 Hospital Gregorio Marañón, Madrid, ES

4 University Hospital Virgen de las Nieves, Granada, ES

5 San Gerardo Hospital - University of Milano-Bicocca, Monza, IT

6 Heinrich Heine University Hospital, Düsseldorf, DE

7 HIV Cure Research Center, Ghent University, Ghent, BE

8 Kings College Hospital, London, UK

9 AUniversity Medical Center Utrecht, Utrecht, NL

10 Cellex, Dresden, DE

11 Pasteur Institute, Paris, FR

 OP 6.2: Sequencing HIV proviruses over time provides new insights into reservoir decay

Authors: D. J. VanBelzen1, S. Weissman1, W.-T. Hwang2, B. Sherman3, U. O’Doherty1

1 Department of Pathology and Cellular Therapeutics, University of Pennsylvania, Philadelphia, PA, US, US

2 Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, US, US

3 Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratories for Cancer Research, Leidos Biomedical Research, Inc. Supporting the Division of Clinical Research, NIAID, US

 OP 6.3: Brief ATI does not alter the size or composition of the latent HIV-1 reservoir

Authors: Katharine J Bar1, Brenda Salantes1, Yu Zheng2, Felicity Mampe1, Subu1 Beg3, Jun Lai3, Randa1 Tressler4, Richard Koup5, James Hoxie1, Mohamed Abdel Mohsen1, Robert Siliciano3, Janet M. Siliciano3, Edgar T. Overton6, and Pablo Tebas1, for the ACTG A5340 clinical trial team.

1 University of Pennsylvania, US

2 Harvard University, US

3 Johns Hopkins University, US

4 National Institutes of Health, US

2 Vaccine Research Center, US

6 University of Alabama Birmingham, US

 OP 6.4: No Residual Virus Replication in a Randomised Trial of Dolutegravir Intensification

Authors: T. A Rasmussen1,2, J. McMahon3, J. Chang1, J. Audsley1, A. Rhodes1, S. Tennakoon1, A. Dantanarayana1, T. Spelman1,3, T. Schmidt4, S. J Kent1,3,5, V. Morcilla5, S. Palmer5, J. Elliott3, S. R Lewin1,3

1 The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, AU

2 Department of Infectious Diseases, Aarhus University Hospital, Aarhus, DK

3 Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, AU

4 Melbourne Sexual Health Centre, Alfred Health, Melbourne, AU

5 Centre for Virus Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, AU

 OP 6.5: A phase 2 trial to evaluate the effects of 3BNC117 in addition to antiretroviral therapy on the latent reservoir and viral rebound

Authors: J. Lorenzi, Y. Cohen, L. Burke, M. Caskey, M. Nussenzweig
The Rockefeller University, New York, US

 OP 6.6: Single Romidepsin infusions do not increase HIV expression in persons on ART (A5315)

Authors: D. McMahon1, L. Zheng2, J. Cyktor J1, E. Aga E2, B.J. Macatangay1, C. Godfrey3, M. Para4, R. Mitsuyasu5, E. Hogg6, J. Hesselgesser7, E. Acosta8, R.T. Gandhi9, J.W. Mellors1 for the A5315 Team

1 University of Pittsburgh, Pittsburgh, PA, US

2 Harvard T.H. Chan Schl Pub Health, Boston, MA, US

3 National Inst of Allergy and Inf Diseases, Bethesda, MD, US

4 Ohio State Univ Med Ctr, Columbus, OH, US

5 UCLA Care Center, Los Angeles, CA, US

6 Social & Scientific Systems, Silver Spring, MD, US

7 Gilead Sciences, Inc., Foster City, CA, US

8 University of Alabama, Birmingham, AL, US

9 Massachusetts General Hospital, Boston, MA, US

FRIDAY DECEMBER 15, 2017

Power Point presentations available only with authors' agreement of publication

8.00

10.00

SESSION 7: NEW THERAPEUTIC APPROACHES I

Chairs: Romas Geleziunas, Senior Director in Biology at Gilead Sciences Foster City, US
Jan Van Lunzen, Global medical Director, ViiV Healthcare, London, UK

 OP 7.0: Early lessons from shock and kill trials

Author: Ole Schmeltz Søgaard
Associate Professor and MD at the Deptartment of Infectious Diseases, Aarhus University Hospital, DK

 OP 7.1: Improved HIV-1 Clearance with BIT225 in the HIV-1 Infected Humanised Mouse Model

Authors: J. Wilkinson1, G. Ewart1, S. Tabruyn2, K. Howangyin2, C. Luscombe1

1 Biotron Limited, Sydney, AU

2 TransCure bioServices SAS, Archamps, FR

 OP 7.2: In vivo suppression of HIV rebound by didehydro-Cortistatin A, a “block-and-lock” strategy for HIV-1 cure

Authors: C.F. Kessing1,5, C.C. Nixon2,5, C. Li1,5, P.M. Tsai2, H. Takata3,4, G. Mousseau1, P.T. Ho2, J.B. Honeycutt2, M. Fallahi1, L.Trautmann3, 4, J.V. Garcia2*, S.T. Valente1, 6*

1 The Scripps Research Institute, Jupiter, FL, US

2 University of North Carolina, School of Medicine, Chapel Hill, NC, US

3 Walter Reed Army Institute of Research, Silver Spring, MD, US

4 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, US

5 These authors contributed equally

 OP 7.3: Properties of eCD4-Ig relevant to reducing the viral reservior

Authors: M. Farzan, M. Gardner, M. Davis-Gardner, C. Fellinger, I. Fetzer
The Scripps Research Institute, Jupiter, Florida, US

 OP 7.4: Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes in lymph nodes and reduces SHIV RNA

Authors: G. Pavlakis1, D.C. Watson1, E. Moysi1,5, A. Valentin1, C. Bergamaschi1, S. Devasundaram1, S.P. Fortis1, J. Bear1, E. Chertova3, J. Bess Jr.3, R. Sowder3, D.J. Venzon4, C. Deleage3, J.D. Estes3, J.D. Lifson3, C. Petrovas5, B.K. Felber1

1 CHuman Retrovirus Section and Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute at Frederick, Frederick, US

3 AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., FNLCR, Frederick, US

4 Biostatistics and Data Management Section, CCR, National Cancer Institute, Rockville, US

5 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, US

 OP 7.5: The human IL-15 superagonist complex ALT-803 drives SIV-specific CD8+ T cells into B cell follicles

Authors: G. Webb1, S. Li2, G. Mwakalundwa2, J.S. Reed1, J.J. Stanton1, A.W. Legasse1, J. Folkvord3, B.S. Park1, M.K. Axthelm1, E.K. Jeng4, H.C. Wong4, J.B. Whitney5, R. Brad Jones6, D.F. Nixon6, E. Connick3, P.J. Skinner2, J.B. Sacha1

1 Oregon Health and Science University, Beaverton, US

2 University of Minnesota, Minneapolis, MN, US

3 University ofArizona, Tucson, AZ, US

4 Altor Bioscience Corporation, Miramar, FL, US

5 Ragon Institute, Harvard Medical School, Cambridge, MA, US

6 George Washington University, Washington DC, US

 OP 7.6: Preclinical Development of a Bispecific HIV x CD3 DART Molecule that Redirects T Cells to Kill HIV Envelope (env)-expressing Cells

Authors: J. L. Nordstrom1, C. Nixon3, J. Pickeral2, Ch.-Y. Kao Lam1, L. Liu1, H. Li1, S. Sharma1, S. Gorlatov1, F. Chen1, K. Sampathkumar1, G. D. Tomaras2, S. M. Alam2, P. Tsai3, T. Morgan3, P.T. Ho3, B. F. Haynes2, G. Ferrari2, J. A. Sung3, D. M. Margolis3, J. Victor Garcia3, S. Koenig1

1 MacroGenics, Inc., Rockville, MD, US

2 Duke University, Durham, NC, US

3 University of North Carolina at Chapel Hill, Chapel Hill, US

10.30

12.30

SESSION 8: NEW THERAPEUTIC APPROACHES II

Chairs: Javier Martinez Picado, AIDS Research Institute irsiCaixa, ICREA & UVic-UCC, Barcelona, ES
Andrea Savarino, National Institute of Health, Roma, IT

 OP 8.0: New therapeutic strategies to cure HIV: so close, so far

Author: J. Martinez Picado
AIDS Research Institute irsiCaixa, ICREA & UVic-UCC, Barcelona, ES

 OP 8.1: HIV-Specific T Cells Generated from HIV-Naive Adult and Cord Blood Donors Target a Range of Novel Viral Epitopes — Implications for a Cure Strategy after Allogeneic HSCT and CBT

Authors: S. Patel1,2, R.B. Jones2, E. Shpall3, D. Margolis3, C.M. Bollard1,2, E. Williams1; S. Albihani1; S. Lam5; J. A.M. Sung3; C. Russell Cruz1,2; R. F. Ambinder5

1 Center for Cancer and Immunology Research, Children’s National Health System, Washington, DC, USR

2 Microbiology, Immunology, and Tropical Medicine, The George Washington University, Washington DC, US

3 University of North Carolina HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, US

4 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, US

5 Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, US

 OP 8.2: Oral ABX464 reduces the HIV DNA reservoir IN CD4+ Peripheral Blood T Cells

Authors: J-M. Steens1, R. Cranston2, J. Martinez-Picado2, R. Paredes2, B. Clotet2, P. Gineste1, H. Ehrlich1, I. McGowan2

1 Abivax, Paris, FR

2 IrsiCaixa Institute for AIDS Research, Badalona, ES

3 University of Pittsburgh, Pittsburgh, US

 OP 8.3: Interim Safety Analysis of Cancer Immunotherapy Trials Network – 12 (CITN-12): A Phase 1 Study of Pembrolizumab in Patients with HIV and Cancer

Authors: T. S. Uldrick1, M. A. “Mac” Cheever2, P.H. Gonçalves1, S. Fling2, K. Aleman1, B. Emu3, M. S. Ernstoff4, R. Gorelick5, J. Kaiser2, H. E Kohrt3, A. Lacroix2, M. Lindsley1, L. M Lundgren2, K. Lurain1, F. Maldarelli7, Ch. Parsons8, E. Sharon9, A. Widell1, R. Yarchoan1

1 National Cancer Institute, HIV & AIDS Malignancy Branch, Bethesda, US

2 Cancer Immunotherapy Trials Network/Fred Hutchinson Cancer Res Center, Seattle, US

3 Yale University, Medicine/Oncology, New Haven, US

4 Roswell Park Cancer Institute, Buffalo, US

5 National Cancer Institute at Frederick, AIDS and Cancer Virus Program, Frederick MD, US

6 Stanford University, Medicine/Oncology, Stanford, US

7 National Cancer Institute, HIV Dynamics and Replication Program, Frederick, MD, US

8 Louisiana State University Health Science Center, New Orleans, US

9 National Cancer Institute, Cancer Therapy and Evaluation Program, Bethesda, US

 OP 8.4: Direct and indirect effects of synthetic dual TLR-2 and TLR-7 agonists (Dual TLR-2/7) on latent HIV

Authors: A. B. Macedo1, C. L. Novis2, A. M. Spivak3, V. Planelles2, J. Szu-han Huang1, Y. Ren1, R. Brad Jones1, A. Bosque1

1 Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, District of Columbia, US

2 Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, US

2 Division of Infectious Diseases, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, US

 OP 8.5: Partial control of viral rebound with a Rev-dependent lentiviral vector carrying HSV-tk gene in SIV-infected rhesus macaques

Authors: Y. Wu1, B. Hetrick1, S. Iqbal2, B. Ling2

1 National Center for Biodefense and Infectious Diseases, School of System Biology, George Mason University, Manassas, US

2 NTulane National Primate Research Center, Covington, US

 OP 8.6: Chronically Treated HIV+ Subjects Can Naturally Harbor Extremely Low Viral Reservoir

Authors: C. Gálvez2, J. Dalmau1, V. Urrea1, B. Clotet1,2,3, L. Leal4, F. García4, J. Martinez-Picado1,3,5, M. Salgado1

1 AIDS Research Institute IrsiCaixa, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, ES

2 Fundació Lluita contra la SIDA, Badalona, ES

3 Universitat de Vic-Central de Catalunya, UVIC-UCC, Vic, ES

4 Infectious Diseases Department, Hospital Clínic, University of Barcelona, Barcelona, ES

5 ICREA, Barcelona, ES


12.30	CLOSING CEREMONY